It is for product, portfolio diversification, there’s revenue diversification, and it’s a great on ramp for our customers. And you know, we’ve had a lot of feedback from the customers that they want more menu for the Cue Health monitoring system, but also just more products. And so really looking forward to rolling this out.
Aasim Javed: Yes, Tejas, Aasim here. I’ll add that our guidance for the first half is predominantly COVID revenue. And this is still early, right, we just announced this. This is still early as we have more to share at the appropriate time we’ll share that.
Tejas Savant: Got it. Thanks, guys. Appreciate the time.
Operator: Thank you. One moment, while we prepare for the next question. Our next question will be coming from Charles Rhyee of Cowen, your line is open.
Unidentified Analyst : Hi, this is Lucas on for Charles. I want to ask about the $100 million and expected OpEx reduction. Should we be thinking that $100 million comes off of your guys as 4x? I’m sorry, fourth quarter OpEx run rate, or rough of 3Q given the increased R&D spend in 4Q? And then how should we think about where that OpEx reduction falls in terms of company’s sales and marketing, R&D and then general and administrator?
Ayub Khattak: Hi, thanks for the question. To start with, we have a strong balance sheet, we have over $240 million in cash, we have $100 million revolving credit facility that’s untapped. We operate without any debt right now. And the good thing is if we think about our spend, from a manufacturing standpoint — manufacturing footprint is already been built. So that’s in the rear view. And it’s also forward compatible with the menu of tests that we’re looking to get approved. So as we think about that, and we look forward, we decided to execute on the cost reduction plan, understanding the macro economic environment, and the need to preserve cash, such that we don’t have a need to enter the capital market in 2023. In terms of how that spend comes in, think about it as the savings kind of accumulate through the quarters.
Unidentified Analyst : Okay, appreciate it. And then, since launching Cue Care, can you guys give us a sense of how much revenue that’s been able to bring as a platform as itself? Not just how it’s resonating in the market, particularly in conversations with employers?
Ayub Khattak: Yes, so we see Cue Care as a really important foundational element to the platform. What it effectively does, it brings the clinician into the experience into the app into the web and allows for people to go from a diagnostic results to actionability instantly, very conveniently. And some of our early wins, like with Minnesota Department of Public Health, we announced that we have a contract with them that was renewed recently, that allow for any Minnesota and to access Cue free of charge, and to be able to talk with the clinician and get medication delivered. And furthermore, when we look at just in general, the integrated Care platform that we’ve been building, the ability to have the clinician on the other side, have a test results, test kit for sexually transmitted infections for heart health and et cetera.
It’s a really important value add. So we’re not really breaking out Cue Care as a specific revenue stream at this time. I think one way of thinking about it is that it’s a really important value add to our existing tests and to the plan test menu.
Operator: Thank you. One moment while we prepare for the next question. Our next question is coming from Matt Sykes of Goldman Sachs. Your line is open.
Matthew Sykes: Hey, good afternoon, everybody. Thanks for taking my questions. Maybe just the first one, if you maybe help us out within the private sector, sort of what the current split is between sort of enterprise consumer and providers and kind of interested in given the reimbursement within the point of care channel, like what type of exposure do you currently have in point of care? And how are the sort of discussions proceeding with that particular end market?